Klaus Pfizenmaier,Harald Wajant,Dieter Moosmayer,Thomas Wuest
申请号：
US14553669
公开号：
US09944708B2
申请日:
2014.11.25
申请国别(地区):
US
年份:
2018
代理人:
摘要：
Subject matter of the invention are antibody-cytokine fusion proteins having proapoptotic and immune modulating properties, but wherein the cytokine moiety a priori has a bioactivity which is very low or restricted to certain receptor subtypes. These reagent exert their full biological activity via the corresponding cytokine receptor(s) only after antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By suitable choice of the antibody specificity, the cytokine activity is directed to the tissue, e.g. tumour tissue, to be treated, and a therapeutic agent can be produced being specifically designed/optimised for the respective indication/tumour entity.
